Form 4 for FBLG FibroBiologics, Inc.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-03-02 · accession 0001493152-26-008646 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-03 | 2026-03-02 | FBLG | Davis Jason | CFO | P - Purchase | $0.41 | +70.0K | 70.0K | New | +$28.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-02 | P | A | 70,000 | $0.41 | 70,000 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3968 to $0.4200 on March 2, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. |